Generic companies ask district court to dismiss Takeda competition claims
Four generic companies have pushed a district court to dismiss competition allegations against them, stating that the latest amendments made by American Sales Company in a class action complaint are “purely cosmetic” and add no new factual allegations.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 February 2026 The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.
19 February 2026 An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.
19 February 2026 The genetic testing firm claims that a former oncology specialist stole hundreds of confidential files in the dead of night, days before moving to a competitor.